In summary, the present study provides evidence for the role of SK2 in Th17 differentiation and suggests that highly potent and selective inhibitors of SK2 might be usefully translated to the clinic to treat psoriasis and other Th17-mediated diseases [46]. Here, SPHK2 is linked to psoriasis.